Wegovy from Novo Nordisk may prevent 1.5 million heart attacks in a decade.
The Revolutionary Weight Loss Drug That Could Save Lives
The groundbreaking weight loss drug Wegovy has the potential to prevent a staggering 1.5 million heart attacks in the United States over the next decade, according to a recent study conducted by scientists at the University of California, Irvine.
“This is a game-changer in the world of obesity and cardiovascular medicine,” said Nathan Wong, the lead author of the study and director of the Heart Disease Prevention Program at UCI School of Medicine. “We now have a weight control therapy that not only helps with weight loss but also significantly reduces the risk of cardiovascular events, going beyond its original focus on the diabetes population.”
Impressive Results and Promising Outlook
The researchers based their findings on a 2021 study of semaglutide, the active ingredient in Wegovy. The study revealed that obese or overweight patients lost an astonishing 15% of their body weight while taking the drug.
Estimating that around 93 million obese or overweight adults in the U.S. would be eligible for semaglutide treatment in the next decade, the study suggests that Wegovy could potentially reduce the number of obese patients by up to 43 million.
Based on this data, the researchers projected that the decrease in the obese population could lead to an 18% reduction in cardiovascular disease, potentially preventing 1.5 million cardiovascular incidents.
Support and Validation
The UCI study received financial support from Novo Nordisk, the manufacturer of semaglutide, as disclosed in the research funding statement.
These findings align with independent research published earlier this month. A worldwide, multiyear study conducted by the research firm SELECT showed that patients on Wegovy were 20% less likely to experience adverse cardiovascular events, such as strokes or heart attacks.
Martin Holst Lange, executive vice president for development at Novo, hailed the worldwide study as “a landmark trial” and emphasized the potential of semaglutide 2.4 mg to revolutionize the treatment of obesity.
Success and Growth
Novo Nordisk has made significant strides this year with its semaglutide products. Wegovy, approved by the Food and Drug Administration at a 2.4 mg dose for weight loss, and Ozempic, FDA approved for insulin-dependent Type 2 diabetes with a semaglutide dose ranging between 0.5 mg and 2 mg.
In the second quarter earnings report, Novo revealed profits exceeding $3.5 billion, with sales surpassing expectations by 3%.
Continued Research and Safety Concerns
Health regulatory boards in the European Union and the United Kingdom are currently investigating semaglutide and similar medications for potential risks of suicidal or self-harm thoughts. It is important to note that these risks are not listed as side effects of either Wegovy or Ozempic.
In addition, a lawsuit was filed against Novo and U.S.-based competitor Eli Lilly this month for stomach paralysis caused by both Ozempic and Lilly’s Mounjaro, which is also used to treat Type 2 diabetes.
Both Novo and Lilly have emphasized their commitment to patient safety and taking these matters seriously.
Click here to read more from The Washington Examiner.
" Conservative News Daily does not always share or support the views and opinions expressed here; they are just those of the writer."
*As an Amazon Associate I earn from qualifying purchases
